T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04

被引：0
|
作者：
Tsurutani, Junji [1 ]
Modi, Shanu [2 ]
Sohn, Joo Hyuk [3 ]
Tokunaga, Eriko [4 ]
Niikura, Naoki [5 ]
Park, Yeon Hee [6 ]
Lee, Keun Seok [7 ]
Chae, Yee Soo [8 ]
Wang, Xiaojia [9 ,10 ]
Li, Wei [11 ]
Im, Seock-Ah [12 ]
Xu, Binghe [13 ]
Lu, Yen-Shen [14 ]
Gambhire, Dhiraj [15 ]
Nishijima, Soichiro [16 ]
Nishiyama, Yuji [16 ]
Sugihara, Masahiro [16 ,17 ]
机构：
[1] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[5] Tokai Univ, Hiratsuka, Kanagawa, Japan
[6] Samsung Med Ctr, Seoul, South Korea
[7] Natl Canc Ctr, Gyeonggi Do, South Korea
[8] Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea
[9] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[10] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[11] 1st Hosp Jilin Univ, Changchun, Peoples R China
[12] Seoul Natl Univ Hosp, Seoul, South Korea
[13] CAMS, Canc Inst & Hosp, Beijing, Peoples R China
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[16] Daiichi Sankyo Co Ltd, Tokyo, Japan
[17] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2-2
引用
收藏
页码：S1379 / S1379
页数：1
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [32] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [33] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [34] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
    Cortes, J.
    Im, S-A.
    Iwata, H.
    Hamilton, E. P.
    Hurvitz, S. A.
    Egorov, A.
    Cathcart, J.
    Liu, Y.
    Bako, E.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S645 - S646
  • [37] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Kim, Sung-Bae
    Chung, Wei-Pang
    Im, Seock-Ah
    Park, Yeon Hee
    Hegg, Roberto
    Kim, Min-Hwan
    Tseng, Ling-Ming
    Petry, Vanessa
    Chung, Chi-Feng
    Iwata, Hiroji
    Hamilton, Erika
    Curigliano, Giuseppe
    Xu, Binghe
    Lee, Caleb
    Liu, Yali
    Cathcart, Jillian
    Bako, Emarjola
    Verma, Sunil
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Impressive improvements in survival for patients with HER2-low metastatic breast cancer-establishing a new subgroup?
    Pervan, M.
    Princk, H.
    Hanker, L.
    Rody, A.
    Buendgen, N.
    Banys-Paluchowski, M.
    ONKOLOGIE, 2023, 29 (02): : 157 - 159
  • [39] Multicenter Retrospective Cohort Study of the Sequential Use of the Antibody-Drug Conjugates (ADCs) Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG) in Patients With HER2-Low Metastatic Breast Cancer (MBC)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [40] Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
    Laura A. Huppert
    Reshma Mahtani
    Samantha Fisch
    Naomi Dempsey
    Sarah Premji
    Angelina Raimonde
    Saya Jacob
    Laura Quintal
    Michelle Melisko
    Jo Chien
    Ana Sandoval
    Lauren Carcas
    Manmeet Ahluwalia
    Natasha Harpalani
    Jenna Hoppenworth
    Anne Blaes
    Kelly Blum
    Mi-Ok Kim
    Dame Idossa
    Ruta Rao
    Karthik V. Giridhar
    Hope S. Rugo
    npj Breast Cancer, 11 (1)
12345